“The present scenario has exposed some structural weaknesses in the EU’s medicines provide chain and also a high dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides claimed. She suggested that offer chain challenges be resolved in an EU pharmaceutical approach predicted t